Zobrazeno 1 - 10 of 39 pro vyhledávání: '"Silvia, Marcé"'
3
Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients
Autor: Marta Cabezón, Cristian Morales, Mónica S. Ventura Ferreira, Natalia Estrada, Rolando Vallansot, Silvia Marcé, Lurdes Zamora, Miguel Sagüés, Concepción Boqué, Fabian Beier, Tim H. Brümmendorf, Olga García, Blanca Xicoy
Publikováno v: Scientia
HemaSphere, Vol 5, Iss 12, p e657 (2021)
HemaSphere
Dipòsit Digital de la UB
Universidad de Barcelona
HemaSphere : open access journal of the European Hematology Association 5(12), e657 (2021). doi:10.1097/HS9.0000000000000657
HemaSphere : open access journal of the European Hematology Association 5(12), e657 (2021). doi:10.1097/HS9.0000000000000657
Published by Wolters Kluwer Health, [Philadelphia, Pennsylvania]
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad32d4a5885bbdc35be5bbc349b82e77
https://hdl.handle.net/11351/9225
Zobrazit plný text záznamu
5
Highly variable mutational profile ofASXL1in myelofibrosis
Autor: C. Fernández, Silvia Marcé, Olga García, Marta Cabezón, Concepción Boqué, Blanca Xicoy, Josep-Maria Ribera, Montserrat Cortés, Esther Plensa, Marc Sorigue, Patricia Velez, Evarist Feliu, Joan Buch, Lurdes Zamora, David Gallardo
Publikováno v: European Journal of Haematology. 97:331-335
OBJECTIVE Somatic mutations in ASXL1 seem to have a negative prognostic impact in patients with several myeloid neoplasms, including myelofibrosis (MF). The aim of this work was to determine the prevalence and profile of ASXL1 mutations in MF. METHOD
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e727f0e28073970e62cbf9af7a03efe2
https://doi.org/10.1111/ejh.12731
Zobrazit plný text záznamu
6
A thirty-five nucleotides BCR-ABL1 insertion mutation of controversial significance confers resistance to imatinib in a patient with chronic myeloid leukemia (CML)
Autor: Montserrat Cortés, Silvia Marcé, Javier Grau, Evarist Feliu, Marta Cabezón, Fuensanta Millá, Lurdes Zamora
Publikováno v: Experimental and Molecular Pathology. 99:16-18
Tyrosine kinase inhibitors (TKI) have improved the management of patients with chronic myeloid leukemia (CML). However, a significant proportion of patients does not achieve the optimal response or are resistant to TKI. ABL1 kinase domain mutations h
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9217e2f107e7abebff8ac1fc47c743
https://doi.org/10.1016/j.yexmp.2015.04.007
Zobrazit plný text záznamu
7
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features
Autor: Lurdes Zamora, Silvia Marcé, Francisco Fuster, Helena Pomares, Marta Cabezón, Anna Sureda, Evarist Feliu, Mar Mallo, Blanca Xicoy, Fuensanta Millá, Rosa Coll, María-José Jiménez, Javier Grau, Laura Palomo, Esther Alonso, Olga García, Francesc Solé, Montse Arnan, Josep-Maria Ribera, Vera Adema, David Gallardo
Publikováno v: Dipòsit Digital de la UB
Universidad de Barcelona
Oncotarget
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
// Laura Palomo 1, 2 , Olga Garcia 3 , Montse Arnan 4 , Blanca Xicoy 3 , Francisco Fuster 1 , Marta Cabezon 3 , Rosa Coll 5 , Vera Adema 1 , Javier Grau 3 , Maria-Jose Jimenez 3 , Helena Pomares 4 , Silvia Marce 3 , Mar Mallo 1 , Fuensanta Milla 3 ,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::784bd2b91dbb8c4d0d9fcdab5ff102a1
http://hdl.handle.net/2445/178606
Zobrazit plný text záznamu
8
The role of T-cell phenotype and T-cell receptor rearrangement in the diagnosis of T-cell malignancies
Autor: Marta Cabezón, Jordi Juncà, Silvia Marcé, Lurdes Zamora, Olga García, Marc Sorigue
Publikováno v: Leukemialymphoma. 57(1)
We read with interest the article by Flammiger et al. [1] on the study of a series of patients with aberrant T-cell phenotype of unclear significance by flow cytometry (FC). They divided their case...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7e00d2e9fa266c2f05ce0ee9e33fa0a
https://pubmed.ncbi.nlm.nih.gov/25971906
Zobrazit plný text záznamu
9
Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis
Autor: Evarist Feliu, Silvia Marcé, C. Fernández, David Gallardo, Concepción Boqué, Fuensanta Millá, Patricia Velez, Marta Cabezón, Lurdes Zamora, Marisol Xandri, Blanca Xicoy
Publikováno v: Leukemialymphoma. 56(10)
In December 2013 mutations were described in the calreticulin (CALR) gene in 67–71% and 56–88% of patients with JAK2 V617F and MPL negative essential thrombocythemia (ET) and primary myelofibrosis ...
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b977caf1cad8e64744bde8888d7e4367
https://pubmed.ncbi.nlm.nih.gov/26077363
Zobrazit plný text záznamu
10
Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells
Autor: Montserrat E, Marçal Pastor-Anglada, I. Huber-Ruano, Silvia Marcé, Beatriz Bellosillo, Joan Gil, Miriam Molina-Arcas, Neus Villamor, Dolors Colomer, F J Casado
Publikováno v: Leukemia
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
Fludarabine is considered the treatment of choice for most patients with chronic lymphocytic leukemia (CLL). We have analyzed the role of plasma membrane transporters in nucleoside-derived drug bioavailability and action in CLL cells. Among the known
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f62f24d1433dd6d978aafbdf978473e
https://doi.org/10.1038/sj.leu.2403582
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje